logo BDSP

Base documentaire

  1. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.

    Article - En anglais


    To identify trends in high-dose therapy with autologous hematopoietic stem-cell support (autotransplants) for breast cancer (1989 to 1995).

    Patients and Methods 

    Analysis of patients who received autotransplants and were reported to the Autologous Blood and Marrow Transplant Registry.

    Between January 1,1989 and June 30,1995,19,291 autotransplants were reviewed ; 5,886 were for breast cancer.

    Main outcomes were progression-free survival (PFS) and survival.


    Between 1989 and 1995, autotransplants for breast cancer increased sixfold.

    After 1992, breast cancer was the most common indication for autotransplant.

    Significant trends included increasing use for locally advanced rather than metastatic disease (P<. 00001) and use of blood-derived rather than marrowderived stem cells (P<. 00001).

    One-hundred-day mortality decreased from 22% to 5% (P<. 0001).

    Three-year PFS probabilities were 65% (95% confidence internals [Cls], 59 to 71) for stage 2 disease, and 60% (95% CI, 53 to 67) for stage 3 disease.

    In metastatic breast cancer, 3-year probabilities of PFS were 7% (95% CI, 4 to 10) for women with no response to conventional dose chemotherapy ; 13% (95% Cl, 9 to 17) for those with partial response ; and 32% (95% CI, 27 to 37) for those with complete response.

    Eleven percent of women with stage 2/3 disease and less than 1% of those with stage 4 disease participated in national cooperative group randomized trials. (...)

    Mots-clés Pascal : Tumeur maligne, Glande mammaire, Chimiothérapie, Anticancéreux, Dose forte, Autogreffe, Cellule hématopoïétique, Cellule souche, Traitement associé, Analyse tendance, Epidémiologie, Pronostic, Registre, Etats Unis, Amérique du Nord, Amérique, Homme, Femelle, Association médicamenteuse, Glande mammaire pathologie, Greffe, Transfusion

    Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Chemotherapy, Antineoplastic agent, High dose, Autograft, Hematopoietic cell, Stem cell, Combined treatment, Trend analysis, Epidemiology, Prognosis, Register, United States, North America, America, Human, Female, Drug combination, Mammary gland diseases, Graft, Transfusion

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0297571

    Code Inist : 002B20E02. Création : 15/07/1997.